SLC22A1

Across TCGA pan-cancer cohorts, SLC22A1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC22A1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC22A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, BRCA, and UCEC are the cancer types where SLC22A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.010	0.784	<.001	24	view →
BRCA	OS	Median	All	0.579	0.963	.008	16	view →
UCEC	DFS	Median	All	0.950	0.612	.005	16	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC22A1–LIHC (OS)

Open the LIHC breakdown →